Login to Your Account



Regeneron, Sanofi kick off skin cancer drug BLA backed by new phase II data

By Michael Fitzhugh
Staff Writer

Wednesday, December 13, 2017

A new FDA filing for the PD-1 checkpoint inhibitor cemiplimab now underway represents more than simple progress for Regeneron Pharmaceuticals Inc. and Sanofi SA

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription